We are pleased to share a progress report about our lead asset GAO-3-02 that has been published in Epilepsia (Bialer et al.,2022; Progress report on new anti-epileptic drugs: A summary of the SixteenthEilat Conference on New Antiepileptic Drugs and Devices: I. Drugs in preclinical and early clinical development).
GAO-3-02 is a first-in-class bioactive lipid developed by GAOMA Therapeutics, with epilepsy and cognitive disorders as initial targeted indications.
https://pubmed.ncbi.nlm.nih.gov/35946083/